Loading in 2 Seconds...
Loading in 2 Seconds...
Country comparison of MeTA baseline pharmaceutical sector scan data. Birgit Kerstens 1 , Samia Saad 2 , Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom. Objective. To provide a cross-country comparative
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Birgit Kerstens1, Samia Saad2, Wilbert Bannenberg1,2
1Health Research for Action (HERA), Belgium;
2Medicines Transparency Alliance (MeTA) Pilot, United Kingdom
To provide a
analysis of the baseline information
about the pharmaceutical sector
in each of the seven
MeTA pilot countries
Individual country pharmaceutical sector scans and the cross-country analysis have been placed in the public domain:
ICIUM abstract: 967
Samia Saad1, Birgit Kerstens2, Wilbert Bannenberg1,2
1Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2HERA, Belgium
Cross country comparison of available disclosed information in core MeTA areas of quality, availability, price and promotion of medicines
List of 37 core indicators developed out of recommended 'key types of data to disclose', listed in instructions and guidance for conducting survey
Data extracted from qualitative information supplied within individual country survey reports into cross country table (EXCEL)
Traffic light analysis applied to cross-country table using where applicable
Green = available and disclosed Orange = available but restricted access Red = not available at all
Cross Country Comparison Table that captures practice on what data is actually disclosed at time surveys were conducted in a ‘Selected Indicators’table
Accompanying ‘Explanatory Notes’ table and a ‘Key Findings’table
1.1 Market registration procedures and registration status of all medicines
Indicator 1. Process for registering and de-registering medicines
1.4 Quality Assurance data during registration or procurement
Indicators 8. & 9.
3.1 Consumer and ex-manufacture prices of medicines in the public, private, and non-profit sectors
Indicator 28. Private sector retail prices for list of key essential medicines
Only Jordan sets medicines retail prices and publishes information though searchable database (but not user friendly).
No information due to lack of systematic price monitoring in Ghana, Kyrgyzstan, Uganda and Zambia.
In Peru and Philippines, partial information available through recently implemented new legislation: Government Maximum Retail Price (Philippines) and recently launched Price Observatory (Peru).
All seven countries have median price ratios of a basket of 30 essential medicines through WHO/HAI surveys conducted within last seven years.
3.3 Medicines price components in public, non-profit, & private sectors
Indicator 34. & 35. Data on price components (duties, taxes, mark-ups and other charges) for key essential medicines (domestically manufactured or imported)
Overall data not available. Only Ghana and Philippines data disclosed through WHO/HAI surveys (specifically included price component data).
Apart from Jordan, countries don’t regulate mark ups on medicines prices. Jordan publishes its regulations but not absolute value of mark ups for individual medicines.
Taxes: Majority of MeTA countries still impose taxes on medicines. Some medicines are tax exempt in Peru; Zambia waives taxes on essential medicines.
4.1 Medicines promotion regulations, policies, and industry practices
Indicator 36. List of manufacturers and distributors that subscribe to internationally or nationally recognized codes of conduct
Information not available in any of the seven MeTA countries.
Indicator 37. Number and type of violations regarding promotional practices and how complaints were resolved
Information not available in any MeTA pilot countries, although all seven countries have guidelines on medicines promotion and regulation criteria for direct to consumer advertising, which is monitored by the regulator.
Monitoring and disclosing violations to ethical guidelines for promotion of medicines weak in all MeTA countries.
All the MeTA Baseline tools are available as part of the ‘Core Tools’ in the MeTAToolkit at www.medicinestransparency.org/meta-toolbox/
Individual Country Baseline Data Disclosure Survey Reports can be found and downloaded at
Country Comparison of MeTA Data Disclosure Survey can be found at